Posted by Michael Wonder on 02 Oct 2024
Zilganersen granted US FDA fast track designation for people living with Alexander disease
1 October 2024 - Zilganersen is the first investigational medicine in clinical development for adults and children living with Alexander disease, an ultra-rare neurological condition.
Ionis Pharmaceuticals announced today that the US FDA has granted zilganersen fast track designation for the treatment of children and adults with an ultra-rare, progressive and ultimately fatal neurological disorder known as Alexander disease.
